Stocklytics Platform
Asset logo for symbol ILMN
Asset logo for symbol ILMN



AI Deep-Learning Forecast (ILMN)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Illumina (ILMN) Stocklytics Forecast

Illumina Inc (ILMN) is a leading company in genetic sequencing and array-based technologies, revolutionizing the field of genomics. With its innovative solutions, Illumina has become a key player in enabling personalized medicine and advancing scientific research. As a result, the stock price of Illumina has garnered significant attention from investors and analysts, sparking interest in predicting its future performance.

When it comes to forecasting the stock price of Illumina Inc, various factors come into play. Analysts often rely on both fundamental analysis and technical analysis to make predictions. Fundamental analysis involves evaluating a company's financial health, industry trends, and competitive landscape. On the other hand, technical analysis focuses on studying historical price and volume patterns to identify potential trends and patterns.

add Illumina  to watchlist

Keep an eye on Illumina

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the analyst price prediction for Illumina (ILMN) stock?

Analysts have set a target price of $190.88 for Illumina (ILMN), based on forecasts from 25 analysts. The predicted price range extends from a high of $300 to a low of $80. This represents a potential increase of up to 158.42% and a decrease of -31.09% from the current price of $116.09. These forecasts are as of 2023 Jun 12.

What are the analyst ratings for Illumina (ILMN) stock?

Currently, there are no analyst ratings available for Illumina (ILMN), possibly due to insufficient coverage or recent updates.

What is the AI price prediction for Illumina (ILMN) stock?

At present, there is no AI or machine-learning-based price prediction available for Illumina (ILMN) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level